Novel treatment options in depression and psychosis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F18%3A00070340" target="_blank" >RIV/65269705:_____/18:00070340 - isvavai.cz</a>

Result on the web

<a href="https://www.dovepress.com/novel-treatment-options-in-depression-and-psychosis-peer-reviewed-article-NDT" target="_blank" >https://www.dovepress.com/novel-treatment-options-in-depression-and-psychosis-peer-reviewed-article-NDT</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/NDT.S157475" target="_blank" >10.2147/NDT.S157475</a>

Result language

angličtina

Original language name

Novel treatment options in depression and psychosis

Original language description

In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets. In depression, treatment resistance to antidepressive pharmacotherapy represents one of the most important clinical challenges. Switching to monotherapy with new multimodal/multifunctional antidepressants and augmentation with new atypical antipsychotics (aripiprazole and brexpiprazole) may be promising options. Further, current evidence supports utility and safety of adjunctive treatment of nutraceuticals. Novel approaches being studied include ketamine and opioids. Recent advances in technology and emerging knowledge about dysfunctional brain circuits and neuroplasticity have led to the development of different new neuromodulation techniques usually used as add-on therapy. Antipsychotics are still the cornerstone of the current treatment of schizophrenia. Two new partial dopamine agonists, brexpiprazole and cariprazine, are now available in addition to aripiprazole. Although the mechanisms of action are similar, the two agents differ in terms of their pharmacodynamic profiles. Further, two new formulations of long-acting injections of second-generation antipsychotics (aripiprazole lauroxil and 3-month paliperidone palmitate) were introduced into clinical practice. New treatment options not yet available include cannabidiol, glutamate modulators, and nicotine receptors agonists.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30215 - Psychiatry

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neuropsychiatric disease and treatment

ISSN

1178-2021

e-ISSN

—

Volume of the periodical

14

Issue of the periodical within the volume

13 MAR

Country of publishing house

NZ - NEW ZEALAND

Number of pages

7

Pages from-to

741-747

UT code for WoS article

000427371200001

EID of the result in the Scopus database

2-s2.0-85044043555